Stay updated on Efgartigimod SC in Bullous Pemphigoid: Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod SC in Bullous Pemphigoid: Clinical Trial page.

Latest updates to the Efgartigimod SC in Bullous Pemphigoid: Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This indicates a minor update to the page.SummaryDifference0.0%

- Check19 days agoChange DetectedResults posted for NCT05681481 BALLAD+ open-label extension, with detailed safety and efficacy outcomes including AEs/SAEs/AESIs, discontinuations due to safety, relapse and remission metrics (CRoff/PRoff, CRmin, sustained remission, BPDAI, IGA-BP, Itch NRS) and time points up to 56 weeks. The page also includes links to the Study Protocol and SAP.SummaryDifference5%

- Check33 days agoChange DetectedA minor version update from v3.4.1 to v3.4.2 was applied to the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 on the page; no substantive content changes observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded Results Submitted and Locations sections to the study page, including state-level site listings (Arizona, California, Florida, Michigan, Missouri, Ohio). Updated to Revision: v3.3.3.SummaryDifference0.6%

Stay in the know with updates to Efgartigimod SC in Bullous Pemphigoid: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod SC in Bullous Pemphigoid: Clinical Trial page.